Yehuda Handelsman to Insulin, Long-Acting
This is a "connection" page, showing publications Yehuda Handelsman has written about Insulin, Long-Acting.
Connection Strength
1.687
-
Lessons from glargine trials: what is the goal fasting glucose with basal insulin? J Diabetes. 2014 Jul; 6(4):271-3.
Score: 0.443
-
Reduced risk of hypoglycemia with insulin degludec versus insulin glargine in patients with type 2 diabetes requiring high doses of basal insulin: a meta-analysis of 5 randomized begin trials. Endocr Pract. 2014 Apr; 20(4):285-92.
Score: 0.442
-
Effect of Insulin Degludec vs Insulin Glargine U100 on Hypoglycemia in Patients With Type 2 Diabetes: The SWITCH 2 Randomized Clinical Trial. JAMA. 2017 Jul 04; 318(1):45-56.
Score: 0.138
-
PATIENTS ACHIEVING GOOD GLYCEMIC CONTROL (HBA1c <7%) EXPERIENCE A LOWER RATE OF HYPOGLYCEMIA WITH INSULIN DEGLUDEC THAN WITH INSULIN GLARGINE: A META-ANALYSIS OF PHASE 3A TRIALS. Endocr Pract. 2015 Aug; 21(8):917-26.
Score: 0.120
-
Health status and hypoglycaemia with insulin degludec versus insulin glargine: a 2-year trial in insulin-na?ve patients with type 2 diabetes. Diabetes Obes Metab. 2014 Sep; 16(9):869-72.
Score: 0.110
-
A comparison of adding liraglutide versus a single daily dose of insulin aspart to insulin degludec in subjects with type 2 diabetes (BEGIN: VICTOZA ADD-ON). Diabetes Obes Metab. 2014 Jul; 16(7):636-44.
Score: 0.109
-
Comparison of insulin degludec with insulin glargine in insulin-naive subjects with Type?2 diabetes: a 2-year randomized, treat-to-target trial. Diabet Med. 2013 Nov; 30(11):1298-304.
Score: 0.107
-
Insulin degludec versus insulin glargine in insulin-naive patients with type 2 diabetes: a 1-year, randomized, treat-to-target trial (BEGIN Once Long). Diabetes Care. 2012 Dec; 35(12):2464-71.
Score: 0.100
-
Cancer mortality and insulin glargine. J Diabetes. 2009 Sep; 1(3):131-3.
Score: 0.079
-
EFFICACY AND SAFETY OF IDEGLIRA IN OLDER PATIENTS WITH TYPE 2 DIABETES. Endocr Pract. 2019 Feb; 25(2):144-155.
Score: 0.038